Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review

Musburger, Brooke G.; Gonzalez Echeandia, Maria; Suskind, Elias L.; Suskind, David L.; Zheng, Hengqi Betty; Mark, Dominique

doi:10.3390/pharmaceutics17060753

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.

Open AccessReview

Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review

by

Brooke G. Musburger

^1,†,

Maria Gonzalez Echeandia

^1,†,

Elias L. Suskind

²

,

David L. Suskind

¹

,

Hengqi Betty Zheng

¹

and

Dominique Mark

^3,*

¹

Division of Pediatric Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USA

²

School of Life Sciences, Arizona State University, 427 E Tyler Mall, Tempe, AZ 85281, USA

³

Department of Pharmacy, Seattle Children’s Hospital, Seattle, WA 98105, USA

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Pharmaceutics 2025, 17(6), 753; https://doi.org/10.3390/pharmaceutics17060753 (registering DOI)

Submission received: 27 March 2025 / Revised: 22 May 2025 / Accepted: 23 May 2025 / Published: 7 June 2025

(This article belongs to the Special Issue Therapeutic Drugs and Delivery Strategies for Gastrointestinal Diseases)

Download Versions Notes

Abstract

Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated disorder that is characterized by symptoms of esophageal dysfunction and the presence of increased eosinophils in the esophageal mucosa. It is becoming increasingly prevalent among children and adults and its pathogenesis arises from the complex interaction of genetic predisposition and environmental triggers, both which contribute to esophageal inflammation. Current societal guidelines recommend the use of proton pump inhibitors, topical steroids, and dietary interventions such as elimination diets as first-line treatments, however, the recent approval of Dupliumab has provided an additional therapeutic avenue. There are a number of investigational biologic agents targeting other immune pathways which are making their way through the pipeline of pharmacologic options in treating this chronic disorder.

Keywords: eosinophilic esophagitis; EoE; EGID

Share and Cite

MDPI and ACS Style

Musburger, B.G.; Gonzalez Echeandia, M.; Suskind, E.L.; Suskind, D.L.; Zheng, H.B.; Mark, D. Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review. Pharmaceutics 2025, 17, 753. https://doi.org/10.3390/pharmaceutics17060753

AMA Style

Musburger BG, Gonzalez Echeandia M, Suskind EL, Suskind DL, Zheng HB, Mark D. Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review. Pharmaceutics. 2025; 17(6):753. https://doi.org/10.3390/pharmaceutics17060753

Chicago/Turabian Style

Musburger, Brooke G., Maria Gonzalez Echeandia, Elias L. Suskind, David L. Suskind, Hengqi Betty Zheng, and Dominique Mark. 2025. "Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review" Pharmaceutics 17, no. 6: 753. https://doi.org/10.3390/pharmaceutics17060753

APA Style

Musburger, B. G., Gonzalez Echeandia, M., Suskind, E. L., Suskind, D. L., Zheng, H. B., & Mark, D. (2025). Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review. Pharmaceutics, 17(6), 753. https://doi.org/10.3390/pharmaceutics17060753

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI